Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease by Wellens, J, Brann, S, Adams, A, Marlow, L, Lindsay, JO, Satsangi, JJ

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic by McGregor, CG, Adams, A, Sadler, R, Arancibia-Cárcamo, CV, Palmer, R, Ambrose, T, Brain, O, Walsh, A, Klenerman, P, Travis, SP, Croft, NM, Lindsay, JO, Satsangi, J

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2... by Wellens, J, Edmans, M, Obolski, U, McGregor, CGC, Simmonds, P, Turner, M, Jarvis, L, Skelly, D, Dunachie, S, Barnes, E, Eyre, DW, Colombel, J-F, Wong, S-Y, Klenerman, P, Lindsay, JO, Satsangi, J, Thompson, CP

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis by Kennedy, NA, Warner, B, Johnston, EL, Flanders, L, Hendy, P, Ding, NS, Harris, R, Fadra, AS, Basquill, C, Lamb, CA, Cameron, FL, Murray, CD, Parkes, M, Gooding, I, Ahmad, T, Gaya, DR, Mann, S, Lindsay, JO, Gordon, J, Satsangi, J, Hart, A, McCartney, S, Irving, P, Lees, CW

Geography influences susceptibility to SARS-CoV-2 serological response in patients with inflammatory bowel disease: multinational analysis from the ICARUS-IBD Consortium by Wong, S-Y, Wellens, J, Helmus, D, Marlow, L, Brann, S, Martinez Pazos, V, Weinberg, A, Moran, HR, McGregor, C, Vermeire, S, Watanabe, K, Kamikozuru, K, Ahuja, V, Vermani, S, Lindsay, JO, Kingston, A, Dutta, U, Kaur, H, Silverberg, MS, Milgrom, R, Chien Ng, S, Mak, JWY, Cadwell, K, Thompson, C, Colombel, J-F, Satsangi, J